Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy
Open Access
- 19 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Abstract
Background: Intestinal dysbiosis might play a pathogenetic role in subjects with symptomatic uncomplicated diverticular disease (SUDD), but the effect of rifaximin therapy has been scantly explored with regard to gut microbiota variations in patients with SUDD.Aims: To verify to which extent rifaximin treatment affects the gut microbiota and whether an electronic multisensorial assessment of stools and breath has the potential for detecting these changes.Methods: Breath and stool samples were collected from consecutive patients with SUDD before and after a 7 days' therapy with rifaximin. Stool microbiota was assessed, and the electronic multisensorial assessment was carried out by means of the BIONOTE electronic (e-)tongue in stools and (e-)nose in breath.Results: Forty-three subjects (female 60%, median age 66 years) were included, and 20 (47%) reported clinical improvement after rifaximin therapy. Alpha and beta diversity of stool microbiota did not significantly change after treatment, while a significant variation of selected taxa was shown (i.e., Citrobacter, Coprococcus, Anaerotruncus, Blautia, Eggerthella lenta, Dehalobacterium, SMB53, and Haemophilus parainfluenzae). Overall, the electronic multisensorial system suboptimally mirrored microbiota changes, but it was able to efficiently predict patients' clinical improvement after rifaximin with accuracies ranging from 0.81 to 0.98.Conclusions: In patients with SUDD, rifaximin administration is associated with significant variation of selected taxa. While inaccurate in predicting gut microbiota change, an electronic multisensorial system, made up of e-tongue and e-nose, was able to predict clinical improvement, thus potentially qualifying as an easy and cheap tool to forecast subjects taking most likely benefit from rifaximin therapy.Keywords
This publication has 38 references indexed in Scilit:
- Italian consensus conference for colonic diverticulosis and diverticular diseaseUnited European Gastroenterology Journal, 2014
- Design and Test of a Biosensor-Based Multisensorial System: A Proof of Concept StudySensors, 2013
- 454 Pyrosequencing Reveals a Shift in Fecal Microbiota of Healthy Adult Men Consuming Polydextrose or Soluble Corn FiberThe Journal of Nutrition, 2012
- Effects of Antibiotics on Shiga Toxin 2 Production and Bacteriophage Induction by Epidemic Escherichia coli O104:H4 StrainAntimicrobial Agents and Chemotherapy, 2012
- Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular diseaseAlimentary Pharmacology & Therapeutics, 2011
- Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanismsBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2010
- QIIME allows analysis of high-throughput community sequencing dataNature Methods, 2010
- PyNAST: a flexible tool for aligning sequences to a template alignmentBioinformatics, 2009
- Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanismAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- DiverticulitisNew England Journal of Medicine, 2007